The effect of an iron supplement on serum aluminum level and desferrioxamine mobilization test in hemodialysis patients

Jeng Yi Huang, Mai Szu Wu, Ching Herng Wu

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background. The serum aluminum (Al) measurement with desferrioxamine (DFO) mobilization is a screening test for uremic patients with an Al overload. In these patients, body iron status is one of the factors affecting the serum Al level. This study is designed to elucidate the effects of iron supplements on the serum Al and the DFO mobilization test. Methods. Our study featured ten hemodialysis patients with iron deficiency anemia. The iron supplement was given intravenously with saccharated ferric oxide, 40 mg three times weekly, at the end of each hemodialysis. The total amount of iron supplement was 1,000 mg. All the patients underwent a DFO test at a dose of 5 mg/kg. The same test was repeated two weeks after completion of the iron supplement. Results. After the iron supplement, patients' iron deficiency anemia improved with a serum ferritin elevation from 312.4 ± 589.5 to 748.2 ± 566.2 μg/L (p <0.01), and iron saturation from 21.6 ± 20.3 to 41.1 ± 21.7 % (p = 0.06). The basal serum Al level decreased from 34.3 ± 13.8 to 21.8 ± 8.5 μg/L (p = 0.01). In the DFO mobilization test, the peak serum Al level decreased from 63.4 ± 19.3 to 50.7 ± 20.5 μg/L (p <0.01). The amount of Al increment (ΔAl) in DFO test was not changed (29.1 ± 12.0 vs. 28.9 ± 15.9 μg/L, p = 0.86). The change in basal Al level tended to negatively correlate with the percentage of increment in iron saturation (r = -0.628, p = 0.05). Conclusion. Results in this study suggest that iron supplements may significantly reduce the basal serum Al and peak Al in DFO mobilization test, without significant change of the mean ΔAl. The data presented indicate that in the interpretation of serum aluminum levels the iron status should be taken into account.

Original languageEnglish
Pages (from-to)789-795
Number of pages7
JournalRenal Failure
Volume23
Issue number6
DOIs
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

Deferoxamine
Aluminum
Renal Dialysis
Iron
Serum
saccharated ferric oxide
Iron-Deficiency Anemias
Ferritins

Keywords

  • Aluminum
  • Desferrioxamine
  • Iron saturation
  • Uremia

ASJC Scopus subject areas

  • Nephrology

Cite this

The effect of an iron supplement on serum aluminum level and desferrioxamine mobilization test in hemodialysis patients. / Huang, Jeng Yi; Wu, Mai Szu; Wu, Ching Herng.

In: Renal Failure, Vol. 23, No. 6, 2001, p. 789-795.

Research output: Contribution to journalArticle

@article{6374e35052c94635baadc8c49e4568b1,
title = "The effect of an iron supplement on serum aluminum level and desferrioxamine mobilization test in hemodialysis patients",
abstract = "Background. The serum aluminum (Al) measurement with desferrioxamine (DFO) mobilization is a screening test for uremic patients with an Al overload. In these patients, body iron status is one of the factors affecting the serum Al level. This study is designed to elucidate the effects of iron supplements on the serum Al and the DFO mobilization test. Methods. Our study featured ten hemodialysis patients with iron deficiency anemia. The iron supplement was given intravenously with saccharated ferric oxide, 40 mg three times weekly, at the end of each hemodialysis. The total amount of iron supplement was 1,000 mg. All the patients underwent a DFO test at a dose of 5 mg/kg. The same test was repeated two weeks after completion of the iron supplement. Results. After the iron supplement, patients' iron deficiency anemia improved with a serum ferritin elevation from 312.4 ± 589.5 to 748.2 ± 566.2 μg/L (p <0.01), and iron saturation from 21.6 ± 20.3 to 41.1 ± 21.7 {\%} (p = 0.06). The basal serum Al level decreased from 34.3 ± 13.8 to 21.8 ± 8.5 μg/L (p = 0.01). In the DFO mobilization test, the peak serum Al level decreased from 63.4 ± 19.3 to 50.7 ± 20.5 μg/L (p <0.01). The amount of Al increment (ΔAl) in DFO test was not changed (29.1 ± 12.0 vs. 28.9 ± 15.9 μg/L, p = 0.86). The change in basal Al level tended to negatively correlate with the percentage of increment in iron saturation (r = -0.628, p = 0.05). Conclusion. Results in this study suggest that iron supplements may significantly reduce the basal serum Al and peak Al in DFO mobilization test, without significant change of the mean ΔAl. The data presented indicate that in the interpretation of serum aluminum levels the iron status should be taken into account.",
keywords = "Aluminum, Desferrioxamine, Iron saturation, Uremia",
author = "Huang, {Jeng Yi} and Wu, {Mai Szu} and Wu, {Ching Herng}",
year = "2001",
doi = "10.1081/JDI-100108190",
language = "English",
volume = "23",
pages = "789--795",
journal = "Renal Failure",
issn = "0886-022X",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - The effect of an iron supplement on serum aluminum level and desferrioxamine mobilization test in hemodialysis patients

AU - Huang, Jeng Yi

AU - Wu, Mai Szu

AU - Wu, Ching Herng

PY - 2001

Y1 - 2001

N2 - Background. The serum aluminum (Al) measurement with desferrioxamine (DFO) mobilization is a screening test for uremic patients with an Al overload. In these patients, body iron status is one of the factors affecting the serum Al level. This study is designed to elucidate the effects of iron supplements on the serum Al and the DFO mobilization test. Methods. Our study featured ten hemodialysis patients with iron deficiency anemia. The iron supplement was given intravenously with saccharated ferric oxide, 40 mg three times weekly, at the end of each hemodialysis. The total amount of iron supplement was 1,000 mg. All the patients underwent a DFO test at a dose of 5 mg/kg. The same test was repeated two weeks after completion of the iron supplement. Results. After the iron supplement, patients' iron deficiency anemia improved with a serum ferritin elevation from 312.4 ± 589.5 to 748.2 ± 566.2 μg/L (p <0.01), and iron saturation from 21.6 ± 20.3 to 41.1 ± 21.7 % (p = 0.06). The basal serum Al level decreased from 34.3 ± 13.8 to 21.8 ± 8.5 μg/L (p = 0.01). In the DFO mobilization test, the peak serum Al level decreased from 63.4 ± 19.3 to 50.7 ± 20.5 μg/L (p <0.01). The amount of Al increment (ΔAl) in DFO test was not changed (29.1 ± 12.0 vs. 28.9 ± 15.9 μg/L, p = 0.86). The change in basal Al level tended to negatively correlate with the percentage of increment in iron saturation (r = -0.628, p = 0.05). Conclusion. Results in this study suggest that iron supplements may significantly reduce the basal serum Al and peak Al in DFO mobilization test, without significant change of the mean ΔAl. The data presented indicate that in the interpretation of serum aluminum levels the iron status should be taken into account.

AB - Background. The serum aluminum (Al) measurement with desferrioxamine (DFO) mobilization is a screening test for uremic patients with an Al overload. In these patients, body iron status is one of the factors affecting the serum Al level. This study is designed to elucidate the effects of iron supplements on the serum Al and the DFO mobilization test. Methods. Our study featured ten hemodialysis patients with iron deficiency anemia. The iron supplement was given intravenously with saccharated ferric oxide, 40 mg three times weekly, at the end of each hemodialysis. The total amount of iron supplement was 1,000 mg. All the patients underwent a DFO test at a dose of 5 mg/kg. The same test was repeated two weeks after completion of the iron supplement. Results. After the iron supplement, patients' iron deficiency anemia improved with a serum ferritin elevation from 312.4 ± 589.5 to 748.2 ± 566.2 μg/L (p <0.01), and iron saturation from 21.6 ± 20.3 to 41.1 ± 21.7 % (p = 0.06). The basal serum Al level decreased from 34.3 ± 13.8 to 21.8 ± 8.5 μg/L (p = 0.01). In the DFO mobilization test, the peak serum Al level decreased from 63.4 ± 19.3 to 50.7 ± 20.5 μg/L (p <0.01). The amount of Al increment (ΔAl) in DFO test was not changed (29.1 ± 12.0 vs. 28.9 ± 15.9 μg/L, p = 0.86). The change in basal Al level tended to negatively correlate with the percentage of increment in iron saturation (r = -0.628, p = 0.05). Conclusion. Results in this study suggest that iron supplements may significantly reduce the basal serum Al and peak Al in DFO mobilization test, without significant change of the mean ΔAl. The data presented indicate that in the interpretation of serum aluminum levels the iron status should be taken into account.

KW - Aluminum

KW - Desferrioxamine

KW - Iron saturation

KW - Uremia

UR - http://www.scopus.com/inward/record.url?scp=0035662752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035662752&partnerID=8YFLogxK

U2 - 10.1081/JDI-100108190

DO - 10.1081/JDI-100108190

M3 - Article

VL - 23

SP - 789

EP - 795

JO - Renal Failure

JF - Renal Failure

SN - 0886-022X

IS - 6

ER -